Maravai postpones Q4/FY2024 earnings, cites material weakness in revenue recognition and potential goodwill impairment

MARAVAI LIFESCIENCES HOLDINGS, INC.

Earnings release and call postponed; 10-K filing delayed until March 18, 2025.
Preliminary FY2024 revenue near midpoint of $255M-$265M guidance.
Additional time needed for goodwill impairment assessment related to Alphazyme LLC acquisition.
Revenue recognition error for ~$3.9M shipment recorded in wrong quarter; no full-year impact.
Assessing effectiveness of internal controls; material weakness in revenue recognition identified.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.